Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-04-17
2007-04-17
Romeo, David (Department: 1647)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S350000
Reexamination Certificate
active
09062113
ABSTRACT:
A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4959314 (1990-09-01), Mark et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5393739 (1995-02-01), Bentz et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5578569 (1996-11-01), Tam
patent: 5599708 (1997-02-01), Mundy et al.
patent: 5658756 (1997-08-01), Rodan et al.
patent: 5843678 (1998-12-01), Boyle
patent: 6017729 (2000-01-01), Anderson et al.
patent: 0514130 (1992-11-01), None
patent: 0727211 (1996-08-01), None
patent: 330400 (1999-05-01), None
patent: WO 96/28546 (1996-09-01), None
patent: WO97/00317 (1997-01-01), None
patent: WO97/00318 (1997-01-01), None
patent: WO 97/23614 (1997-07-01), None
patent: 98 07840 (1997-08-01), None
patent: EP 0816 380 (1998-01-01), None
International Search Report for PCT/JP98/01728.
Simonet et al., “Osteoprotegerin: a novel secreted protein involved in the regulation of bone density,” CELL, vol. 89, Apr. 18, 1997, pp. 309-319.
Reddi, “Bone morphogenesis and modeling: soluble signals sculpt osteosomes in the solid state,” CELL, vol. 89, Apr. 18, 1997, pp. 159-161.
Chambers et al., “Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2btsA58 transgenic mouse,” Proceed. of the National Acad. of Sciences of USA, vol. 90, Jun. 1993, pp. 5578-5582.
Smith et al., “The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death,” CELL, vol. 76, Mar. 25, 1994, pp. 959-962.
Goodwin et al., “Molecular cloning and expression of the type 1 and type 2 receptors for tumor necrosis factor,” Database EMROD, EMBL Databases, Accession No. M59378, Jun. 28, 1991.
Chenu et al., “Transforming growth factor β inhibits formation of osteoclast-like cells in long-term human marrow cells,” Proceed. of the National Acad. of Sciences of USA, vol. 85, Aug. 1998, pp. 5683-5687.
Gowen et al., “Preferential Inhibition of Cytokine-Stimulated Bone Resorption by Recombinant Interferon Gamma,” Journal of Bone and Mineral Research, vol. 1, No. 5, 1986, pp. 469-474.
Hattersley et al., “Human Macrophage Colony-Stimulating Factor Inhibits Bone Resorption by Osteoclasts Disaggregated From Rat Bone,” Journal of Cellular Physiology, vol. 137, No. 1, Oct. 1998, pp. 199-203.
Takada et al., “A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells,” Bone and Mineral, vol. 17, 1992, pp. 347-359.
Kasono et al., “Inhibitory effect of interleukin-4 on osteoclast-like cell formation in mouse bone marrow culture,” Bone and Mineral, vol. 21, 1993, pp. 179-188.
Watanabe et al., “Interleukin-4 as a Potent Inhibitor of Bone Resorption,” Biochem. and Biophys. Research Comm., vol. 172, No. 3, Nov. 1990, pp. 1035-1041.
F.W. Fawthrop et al., “The Effect of Transforming Growth Factor β on the Plasminogen Activator Activity of Normal Human Osteoblast-like Cells and a Human Osteosarcoma Cell Line MG-63”J. Bone and Mineral Res. 7(12):1363-1371 (1992).
A.J. Fenton et al., “Long-Term Culture of Disaggregated Rat Osteoclasts: Inhibition of Bone Resorption and Reduction of Osteoclast-Like Cell Number by Calcitonin and PTHrP[107-139]”J. Cellular Phys. 155:1-7 (1993).
T. Suda et al., “Modulation of Osteoclast Differentiation by Local Factors”Bone 117(2 Supp.):87S-91S (1995).
E. Tsuda et al., “Isolation of a Novel Cytokine from Human Fibroblasts that Specifically Inhibits Osteoclastogenesis”Biochem. and Bioiphys. Res. Comm. 234:137-142 (1997).
Adams, M.D. et al., “Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project”,Science, vol. 252, Jun. 21, 1991, pp. 1651-1656.
Anderson et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function”,Nature, vol. 390, Nov. 13, 1997, pp. 175-179.
Database on GenEmbl, Anderson et al. Accession No. AF019048 Mus musculus receptor activator of nuclear factor kappa B ligand RANKL), Nov. 22, 1997.
George et al.,Macromolecular Sequencing and Synthesis, New York, 1998, p. 127-149.
Kaji et al., “Insulin-like growth factor-I mediates osteoclast-like cell formation stimulated by parathyroid hormone”,Journal of Cellular Physiology, vol. 172, No. 1, Jul. 10, 1997, pp. 55-62.
Kukita et al., “Osteoinductive factor inhibits formation of human osteoclast-like cells”,Proc. Natl. Acad. Sci. USA, vol. 87, Jan. 29, 1990, pp. 3023-3026.
Lewis et al., “Cloning and expression of cDNAS for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific”,Proc. Natl. Aca. Sci. USA, vol. 88, 1991, pp. 2830-2834.
Rieger et al.,Glossary of Genetics and Cytogenetics, Springer-Verlag, Berlin Heidlberg New York, 1976, p. 17.
Wong et al., “TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cell”,J.Biol. Chem., vol. 272, No. 40, Oct. 28, 1997, pp. 24727-25408.
Yoneda, Toshiyuki, et al., “Sumarin Suppresses Hypercalcemia and Osteoclastic Bone Resorption in Nude Mice Bearing a Human Squamous Cancer”, vol. 55, May 1, 1995, pp. 1989-1993,Cancer Research.
Goto Masaaki
Higashio Kanji
Kobayashi Fumie
Mochizuki Shin′ichi
Morinaga Tomonori
Arnold & Porter LLP
Romeo David
Sankyo Co. Ltd.
LandOfFree
Proteins and methods for producing the proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proteins and methods for producing the proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteins and methods for producing the proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3794239